Effectiveness of Tuberculosis Financing on Reducing Tuberculosis Incidence in Asia and Africa: A Systematic Review
DOI:
https://doi.org/10.35451/4mvhff85Keywords:
Tuberculosis, health financing, catastrophic costs, TB control, Asia-AfricaAbstract
Tuberculosis (TB) remains a significant global health burden, particularly in Asia and Africa, which account for the majority of TB cases worldwide. Financing gaps, limited financial protection mechanisms, and dependence on international donors continue to pose major challenges to achieving the 2030 TB elimination targets. Catastrophic costs among households affected by TB remain high, especially in low- and middle-income countries across these regions. Objective: This systematic review aims to assess the effectiveness of TB financing in supporting various TB control program scenarios and its impact on reducing TB incidence in countries across Asia and Africa. Methods: The study was conducted in accordance with PRISMA 2020 guidelines. Literature searches were carried out in four international databases (PubMed, Scopus, ScienceDirect, and ProQuest) for publications from 2014 to 2024. Of the 2,227 identified articles, 29 studies met the inclusion criteria. The included studies comprised economic evaluations (cost-effectiveness and cost-utility analyses), cohort studies, randomized controlled trials, and cross-sectional studies. Methodological quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. Results: The synthesis indicates that TB financing from multiple sources—such as central government Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided the original work is properly cited.budgets and international donors (Global Fund, WHO, USAID, UNICEF, Global Drug Facility/GDF, TB REACH/Stop TB Partnership, PEPFAR, the Bill and Melinda Gates Foundation, the UK Department for International Development), as well as World Bank loans—has supported the implementation of various TB control strategies. These include shorter treatment regimen trials in India, incentive-based active case finding in Pakistan, and community-based care models in South Africa. Such financing mechanisms contributed to increased case notification rates, improved treatment success, and reductions in TB incidence. However, catastrophic costs persist, primarily due to income loss and transportation expenses. The sustainability of TB programs in Asia and Africa depends largely on increased domestic financing, strengthened social protection mechanisms, and more efficient fund allocation through strategic purchasing approaches
Downloads
References
[1] World Health Organization, “TB financing: Financing needs & gaps; International donor funding,” Global Tuberculosis Report 2024, WHO, 2024.
[2] World Health Organization, “The second national TB inventory study in Indonesia,” WHO, 2024.
[3] Kementerian Kesehatan Republik Indonesia, “Gerakan Indonesia Akhiri TBC,” Kemenkes RI, 2025.
[4] Tim Kerja TBC Kemenkes RI, Laporan Program Penanggulangan Tuberkulosis Tahun 2023, Kemenkes RI, Dec. 2024.
[5] T. Tanimura, E. Jaramillo, D. Weil, M. Raviglione, and K. Lönnroth, “Financial burden for tuberculosis patients in low- and middle-income countries: A systematic review,” Eur. Respir. J., vol. 43, no. 6, pp. 1763–1775, 2014.
[6] R. M. Ghazy, H. M. El Saeh, S. Abdulaziz, et al., “A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients,” Sci. Rep., vol. 12, p. 558, 2022.
[7] W. A. Wells, et al., “The intersection of TB and health financing: Defining needs and opportunities,” PLOS Glob. Public Health, vol. 4, no. 5, e0003123, 2024.
[8] The Global Fund, Results Report 2024, The Global Fund, 2024.
[9] S. Saragih, F. Hafidz, A. Nugroho, et al., “Estimating the budget impact of a Tuberculosis strategic purchasing pilot study in Medan, Indonesia (2018–2019),” Health Econ. Rev., vol. 14, p. 44, 2024.
[10] World Bank, “Innovative financing for Tuberculosis pilot in Indonesia,” World Bank, Aug. 29, 2023.
[11] Penabulu Foundation, “Community PR for TB Elimination in Indonesia 2024–2026 (Grant summary),” Penabulu, 2024.
[12] W. B. Wang, et al., “Cost-effectiveness of the Health X Project for tuberculosis control in China,” Int. J. Tuberc. Lung Dis., vol. 18, no. 8, pp. 939–945, 2014.
[13] S. Chatterjee, et al., “Costs of TB services in India,” Int. J. Tuberc. Lung Dis., vol. 25, no. 12, pp. 1013–1018, 2021.
[14] S. Kohler, N. Sitali, and N. Paul, “A framework for assessing import costs of medical supplies and results for a tuberculosis program in Karakalpakstan, Uzbekistan,” Health Data Sci., 2021.
[15] Hussain, et al., “The cost-effectiveness of incentive-based active case finding for tuberculosis (TB) control in the private sector Karachi, Pakistan,” BMC Health Serv. Res., vol. 19, p. 690, 2019.
[16] I. Devoid, et al., “The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia,” Int. J. Tuberc. Lung Dis., vol. 26, no. 12, pp. 1162–1169, 2022.
[17] J. Chirenda, et al., “Time-driven activity-based costing for TB services in Zimbabwe,” BMC Health Serv. Res., vol. 21, p. 242, 2021.
[18] L. Bahrainwala, et al., “Drones and digital adherence monitoring for community-based tuberculosis control in remote Madagascar: A cost-effectiveness analysis,” PLoS ONE, vol. 15, no. 7, e0235572, 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Salma Nusaiba, Budi Hidayat, Mufti As Siddiq M Irzal, Anggie Hardiyanti, Jihannisa Aurellia Suharno
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright in each article is the property of the Author.
